Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

June 30th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

June 30th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

November 20th 2012

Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study

Katrina A.B. Goddard, PhD Erin J. Aiello Bowles, MPH Heather Spencer Feigelson, PhD, MPH Laurel A. Habel, PhD Sharon Hensley Alford, PhD Catherine A. McCarty, PhD, MPH Larissa Nekhlyudov, MD, MPH Adedayo A. Onitilo, MD, MSCR, FACP Alanna K. Rahm, PhD, MS Jennifer A. Webster, MS

Evaluation of real-world implementation of HER2 testing showed that uptake was high (>90%) and trastuzumab treatment was targeted to patients with positive HER2 status.

November 20th 2012

Trends in the 2012 Eisai Oncology Digest: Insurance and Cost Obstacles in Cancer Treatment

This article was sponsored by Eisai Inc. The 2012 Eisai Oncology Digest was commissioned funded by Eisai Inc.

November 19th 2012

Payer Management of Oncology: An In-Depth Look

On Friday, November 16, The American Journal of Managed Care hosted its first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology." The conference, which brought together stakeholders from all sides of the managed care industry, provided an arena for healthcare professionals to discuss new, innovative payment models being utilized by both payers and providers.

November 19th 2012

Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that there is a tremendous amount of waste in the system.

November 19th 2012

Peter Bach, MD, MAPP, Talks About Improving Quality in Cancer Care

Peter B. Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Attending Physician, Memorial Sloan-Kettering Cancer Center, states that any organizational change that shifts payment and risk to providers will improve quality.

November 19th 2012

Automated Telephone Calls to Enhance Colorectal Cancer Screening: Economic Analysis

David H. Smith, RPh, PhD Adrianne C. Feldstein, MD, MS Nancy Perrin, PhD A. Gabriela Rosales, MS David M. Mosen, PhD, MPH Elizabeth G. Liles, MD Jennifer L. Schneider, MPH Jennifer E. Lafata, PhD Ronald E. Myers, PhD Russell E. Glasgow, PhD

Automated telephone calls can increase colorectal cancer screening rates at a cost of about $40 per additional screen.

November 19th 2012

Mark Fendrick, MD, Discusses Value-Based Insurance Design

Dr. Mark Fendrick, MD, Professor of Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan, Co-Editor-in-Chief, The American Journal of Managed Care, says that there are levers organizations and stakeholders can pull to achieve the goal of improving quality and value in cancer care.

November 16th 2012

Michael Chernew, PhD, Discusses Challenges in Oncology Management

Michael Chernew, PhD, Professor of Health Care Policy, Harvard Medical School, Vice Chairman, MEDPAC, Co-Editor-in-Chief, The American Journal of Managed Care, says that patients want access to expensive drugs that can help expand and improve their lives.

November 16th 2012

Ira Klein, MD, Discusses Quality Measures in Oncology

Ira Klein, MD, MBA, FACP, Chief Medical Officer, National Accounts Clinical Sales & Strategy, Aetna, addresses measurement programs used in oncology.

November 16th 2012

Dennis Scanlon, PhD, Addresses the Importance of Payer/Provider Relationships

Dennis Scanlon, PhD, Professor of Health Policy and Administration, The Pennsylvania State University, says it is very important to bridge the gap between providers and payers in oncology management.

November 13th 2012

Celgene Stock Soars on Promising Pancreatic Cancer Drug Data

November 12th 2012

Not Enough Cancer Drugs, Too Many Price Controls

October 29th 2012

Pricey New Prostate Cancer Therapy Raises Questions About Safety, Cost

October 24th 2012

Change to FIT Increased CRC Screening Rates: Evaluation of a US Screening Outreach Program

Elizabeth G. Liles, MD, MSCR Nancy Perrin, PhD Ana Gabriela Rosales, MS Adrianne C. Feldstein, MD, MS David H. Smith, RPh, MHA, PhD David M. Mosen, PhD, MPH Jennifer L. Schneider, MPH

Fecal immunochemical testing resulted in higher colorectal cancer screening rates than did guaiac fecal occult blood tests, with less dependence on office visits.

October 11th 2012

Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market

In this video, Aimee Tharaldson, PharmD, discusses some of the current trends in the specialty pharmacy market. In addition, Dr. Tharaldson specifically comments on the oncology pipeline, which currently has the most activity.

October 11th 2012

Therapeutic Vaccine Shows Potential in Fighting Cervical Cancer

October 10th 2012

3-D Mammograms Offer a New Option for Breast Cancer Screening

October 5th 2012

The Evolving Role of the Pharmacist in Oncology Care

The role of the pharmacist in the care of patients with cancer is evolving. Pharmacists can help optimize treatment outcomes for each patient through use of patient-specific and disease-specific strategies.

October 3rd 2012

Cancer Treatment Speeded by Genome Superhighway: Creator

October 3rd 2012

Prostate-Cancer Test May Reduce Repeat Biopsies: Study

October 1st 2012

Roche's Breast Cancer Franchise Boosted by Trial Data

September 27th 2012

Five-Cent Diabetes Pill From 1958 May Be New Cancer Drug

September 20th 2012

Crizotinib Active in ALK-Positive Pediatric Cancer

Silas Inman

September 20th 2012

Oncology Leaders Praise Health Law Ruling-With Caveats

Beth Fand Incollingo

September 20th 2012

State-Level Projections of Cancer-Related Medical Care Costs: 2010 to 2020

Justin G. Trogdon, PhD Florence K. L. Tangka, PhD Donatus U. Ekwueme, PhD Gery P. Guy Jr, PhD Isaac Nwaise, PhD Diane Orenstein, PhD

State-level estimates of the number of people treated for cancer and the average cost of their treatment by state from 2010 through 2020.

September 20th 2012

How Can We Get Better Value in End-of-Life Care?

Stanton R. Mehr

September 20th 2012

Down the Road for Breast Cancer

Michael Marlan Mohundro, PharmD Brice Labruzzo Mohundro, PharmD

Targeted Therapies to Further Improve Outcomes

September 20th 2012

How Payers and Oncologists Really Feel About Oncology Pathways

Kim Farina, PhD

September 20th 2012

Partnering With a Payer to Develop a Value-Based Medical Home Pilot: A West Coast Practice's Experience

Linda D. Bosserman, MD, FACP Diana Verrilli Wendy McNatt

September 20th 2012

Oncology Patient-Centered Medical Home

John D. Sprandio, MD, FACP

...

176 177 178 179 180 181 182 183 184

...

186 >